| abstract |
The present invention provides a method for treating moderate to severe eosinophilic asthma in a patient, which comprises intravenous or subcutaneous administration of about 0.3 to 3 mg / kg of reslizumab to the patient, wherein at least one month has occurred in the patient 12 months prior to administration increased asthma requiring oral, intramuscular, or intravenous administration of a corticosteroid, but prior to this administration, the patient’s asthma symptoms are not adequately controlled by the current anti-asthma drug and blood eosinophils levels are 400 / μl or more. |